On November 20, 2018 Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, reported that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at upcoming investor conferences, will hold a key opinion leader (KOL) event for the investment community, and will present data at the upcoming 60th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (Press release, Aptose Biosciences, NOV 20, 2018, View Source [SID1234531491]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Piper Jaffray 19th Annual Health Care Conference
Time: 4:00 pm ET
Date: Tuesday, November 27, 2018
Live Webcast: Piper Jaffray Conference Aptose Webcast Link
BMO Capital Markets Prescriptions for Success Healthcare Conference
Time: 11:40 am ET
Date: Wednesday, December 12, 2018
Live Webcast: BMO Capital Markets Aptose Webcast Link
Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers
Time: 9:00 – 10:30 am ET
Date: Wednesday, December 12, 2018
Location: Lotte New York Palace Hotel, New York, NY
Live Webcast: Aptose KOL Presentation Webcast Link
The KOL event hosted by Aptose will feature Brian Druker, M.D, Director of Oregon Health & Science University’s Knight Cancer Institute. Dr. Druker is well known for his pioneering role in developing Gleevec for patients with chronic myeloid leukemia (CML) and for his efforts to accelerate the development of novel therapies for the treatment of acute myeloid leukemia (AML). At the KOL event, Dr. Druker will discuss the evolution of kinase inhibitors as anticancer drugs, review the current treatment landscape in AML and B-cell cancers, examine the unmet medical needs for these patient populations, and highlight his experience with Aptose’s CG-806 to potentially address these treatment challenges. Following Dr. Druker, the Aptose Biosciences management team will provide an update on CG-806, which is expected to enter clinical studies in early 2019.
The breakfast event is by invitation only (contact Morgen Alden, [email protected]) and will also be accessible by webcast.
American Society of Hematology (ASH) (Free ASH Whitepaper) Meeting
Time: 6:00 – 8:00 pm PT
Date: December 2, 2018
Location: San Diego Convention Center, San Diego, CA
Aptose previously announced that preclinical data for its pan-FLT3/pan-BTK inhibitor CG-806 will be presented in two separate posters at the 60th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition on Sunday, December 2, 2018 from 6:00-8:00 pm PT in San Diego, CA (link to announcement).